Fabry's disease: Difference between revisions
Jump to navigation
Jump to search
| Line 32: | Line 32: | ||
==Diagnosis== | ==Diagnosis== | ||
===Physical Examination=== | ===Physical Examination=== | ||
=== Laboratory Findings === | === Laboratory Findings === | ||
Revision as of 18:55, 22 August 2012
Template:DiseaseDisorder infobox
|
Fabry's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fabry's disease On the Web |
|
American Roentgen Ray Society Images of Fabry's disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]
Synonyms and keywords: Anderson-Fabry disease; angiokeratoma corporis diffusum universale; alpha-galactosidase A deficiency; ceramide trihexosidase deficiency; hereditary dystopic lipidosis; GLA deficiency; Sweeley-Klionsky disease
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Diagnosis
Physical Examination
Laboratory Findings
- Blood tests
- Anemia
- Serum creatinine may be raised from chronic renal failure
- Serum urea may be elevated
- BUN may be raised
- Urinalysis:
ECG abnormalities
- AV node conduction block
- PR interval shortening
- Arrhythmias
Ultrasound
Treatment
- Until recently, treatment of Fabry's disease targeted the symptomatic effects. However, it is currently being treated at the cellular level through enzyme replacement therapy using Agalsidase alpha (Replagal) and Agalsidase beta (Fabrazyme®).
- The cost of these drugs is problematic (approximately $170,000 US a year/patient) and remains a barrier to many patients in some countries. Enzyme replacement therapy (typically infused every two weeks) may be performed in the patient's home by the patients themselves. Enzyme replacement therapy is not a cure, and must be infused recurrently for maximum benefit.
References
External links
- Fabry Support & Information Group
- Template:NINDS
- Fabry's disease at NLM Genetics Home Reference
- Fabry's Disease Association